{"id":"azasetron","rwe":[],"tags":[{"label":"azasetron","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"5-hydroxytryptamine receptor 3A","category":"target"},{"label":"HTR3A","category":"gene"},{"label":"Active","category":"status"},{"label":"Antiemetics","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Gastrointestinal Agents","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Serotonin Agents","category":"pharmacology"},{"label":"Serotonin Antagonists","category":"pharmacology"}],"phase":"phase_2","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"nazasetron","offLabel":[],"synonyms":["azasetron hydrochloride","azasetron","nazasetron","azasetron HCl"],"timeline":[],"aiSummary":"Nazasetron, also known as AZASETRON, is a small molecule drug that targets the 5-hydroxytryptamine receptor 3A. It belongs to the azasetron class and is used to treat certain conditions. However, its commercial status and approved indications are unknown. Further research is needed to determine its safety profile and potential side effects. As a result, it is not currently available in the market.","brandName":"Nazasetron","ecosystem":[],"mechanism":{"target":"5-hydroxytryptamine receptor 3A","targets":[{"gene":"HTR3A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 3A","protein":"5-hydroxytryptamine receptor 3A"}],"modality":"Small Molecule","drugClass":"azasetron","explanation":"Imagine your body has a system of locks and keys. The 5-hydroxytryptamine receptor 3A is like a lock, and serotonin is the key. Nazasetron is a key that blocks the lock, preventing serotonin from triggering certain responses in the body.","oneSentence":"Nazasetron works by binding to the 5-hydroxytryptamine receptor 3A, blocking its action and reducing symptoms.","technicalDetail":"Nazasetron acts as a selective 5-HT3 receptor antagonist, competing with serotonin for binding sites on the receptor and inhibiting its activation, which is involved in the regulation of various physiological processes including nausea and vomiting."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/267","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=AZASETRON","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AZASETRON","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:47:51.104680","biosimilars":[],"competitors":[{"drugName":"alosetron","drugSlug":"alosetron","fdaApproval":"2000-02-09","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"amoxapine","drugSlug":"amoxapine","fdaApproval":"1980-09-22","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"aripiprazole","drugSlug":"aripiprazole","fdaApproval":"2002-11-15","patentExpiry":"Sep 24, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"asenapine","drugSlug":"asenapine","fdaApproval":"2009-08-13","patentExpiry":"Sep 22, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"astemizole","drugSlug":"astemizole","fdaApproval":"1988-12-31","relationship":"same-target"},{"drugName":"bupivacaine","drugSlug":"bupivacaine","fdaApproval":"1972-10-03","patentExpiry":"Mar 17, 2042","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"chlorpromazine","drugSlug":"chlorpromazine","fdaApproval":"1957-09-18","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"clozapine","drugSlug":"clozapine","fdaApproval":"1989-09-26","patentExpiry":"May 1, 2028","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"diltiazem","drugSlug":"diltiazem","fdaApproval":"1982-11-05","genericCount":38,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"dolasetron","drugSlug":"dolasetron","fdaApproval":"1997-09-11","patentStatus":"Unknown","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"azasetron","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"alosetron","brandName":"alosetron","genericName":"alosetron","approvalYear":"2000","relationship":"same-target"},{"drugId":"amoxapine","brandName":"amoxapine","genericName":"amoxapine","approvalYear":"1980","relationship":"same-target"},{"drugId":"aripiprazole","brandName":"aripiprazole","genericName":"aripiprazole","approvalYear":"2002","relationship":"same-target"},{"drugId":"asenapine","brandName":"asenapine","genericName":"asenapine","approvalYear":"2009","relationship":"same-target"},{"drugId":"astemizole","brandName":"astemizole","genericName":"astemizole","approvalYear":"1988","relationship":"same-target"},{"drugId":"bupivacaine","brandName":"bupivacaine","genericName":"bupivacaine","approvalYear":"1972","relationship":"same-target"},{"drugId":"chlorpromazine","brandName":"chlorpromazine","genericName":"chlorpromazine","approvalYear":"1957","relationship":"same-target"},{"drugId":"clozapine","brandName":"clozapine","genericName":"clozapine","approvalYear":"1989","relationship":"same-target"},{"drugId":"diltiazem","brandName":"diltiazem","genericName":"diltiazem","approvalYear":"1982","relationship":"same-target"},{"drugId":"dolasetron","brandName":"dolasetron","genericName":"dolasetron","approvalYear":"1997","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT05628233","phase":"PHASE2","title":"SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease","status":"COMPLETED","sponsor":"Sensorion","startDate":"2022-12-30","conditions":["Hearing Loss Ototoxic"],"enrollment":48,"completionDate":"2025-06-11"},{"nctId":"NCT05258773","phase":"PHASE2","title":"Evaluation of the Presence of SENS-401 in the Perilymph","status":"COMPLETED","sponsor":"Sensorion","startDate":"2022-08-10","conditions":["Hearing Loss"],"enrollment":28,"completionDate":"2024-05-31"},{"nctId":"NCT06398834","phase":"PHASE4","title":"Esketamine and Butorphanol for Post-Lobectomy Pain","status":"COMPLETED","sponsor":"Second People's Hospital of Hefei City","startDate":"2022-03-01","conditions":["Esketamine","Pain","Post-thoracotomy Pain Syndrome","Thoracic Diseases"],"enrollment":223,"completionDate":"2024-01-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"007693","UNII":"77HC7URR9Z","CHEBI":"CHEBI:31246","INN_ID":"7005","UMLSCUI":"C0378974","ChEMBL_ID":"CHEMBL1598608","KEGG_DRUG":"D01613","DRUGBANK_ID":"DB16837","PUBCHEM_CID":"2264","IUPHAR_LIGAND_ID":"2285","SECONDARY_CAS_RN":"123040-16-4","MESH_SUPPLEMENTAL_RECORD_UI":"C070671"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}